Pacira Pharmaceuticals Company Profile (NASDAQ:PCRX)

Analyst Ratings

Consensus Ratings for Pacira Pharmaceuticals (NASDAQ:PCRX) (?)
Ratings Breakdown: 1 Sell Rating(s), 2 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $77.73 (114.42% upside)

Analysts' Ratings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Show:
DateFirmActionRatingPrice TargetActions
7/28/2016BMO Capital MarketsReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2016MizuhoReiterated RatingBuy$64.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2016WedbushReiterated RatingOutperform$105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/1/2016Brean CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/20/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/28/2016NomuraReiterated RatingBuy$100.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2016Bank of America Corp.UpgradeNeutral -> Buy$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016Piper Jaffray Cos.Reiterated RatingOverweight$93.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/9/2016Leerink SwannReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/6/2016JMP SecuritiesReiterated RatingMkt Outperform$92.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2015Barclays PLCReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2015Jefferies GroupReiterated RatingBuy$81.00 -> $72.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/30/2015Goldman Sachs Group Inc.Boost Price Target$126.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016Q216$0.03$67.80 millionListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2016Q116$0.07$0.15$67.11 million$65.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415$0.27$0.20$68.40 million$69.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2015Q315$0.15$0.10$60.44 million$62.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215$0.04$0.20$62.97 million$59.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115$0.02$0.05$61.11 million$58.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q4$0.27$0.35$61.62 million$61.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314$0.10$0.14$52.20 million$52.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214($0.21)$0.04$42.20 million$47.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q1($0.32)($0.19)$35.40 million$36.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2014Q4($0.31)($0.33)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313($0.35)($0.30)$22.10 million$23.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012Q312($0.44)($0.49)$7.85 million$8.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.20)($0.20)($0.20)
Q3 20161($0.15)($0.15)($0.15)
Q4 20161($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pacira Pharmaceuticals (NASDAQ:PCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/7/2016Lauren Bullaro RikerVPSell938$47.66$44,705.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Kristen Marie WilliamsCAOSell600$47.20$28,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Lauren Bullaro RikerVPSell321$47.20$15,151.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Mark A KronenfeldDirectorSell900$46.95$42,255.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016David M StackCEOSell25,000$64.14$1,603,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2016Scott BraunsteinSVPBuy2,000$58.92$117,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2016James B JonesSVPBuy500$62.50$31,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016David M. StackCEOSell15,000$63.84$957,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016James B JonesSVPBuy1,000$66.00$66,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016John P Phd LongeneckerDirectorBuy300$66.55$19,965.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015David M. StackCEOSell15,000$37.57$563,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2015James S ScibettaCFOBuy5,000$61.37$306,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Paul J HastingsDirectorSell3,000$60.02$180,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015David M StackCEOSell15,000$67.78$1,016,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015David M StackCEOSell25,000$90.50$2,262,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015Paul J HastingsDirectorSell2,500$88.00$220,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Lauren Bullaro RikerDirectorSell5,000$95.34$476,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2015Gary W PaceDirectorBuy1,000$93.83$93,830.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015James S ScibettaCFOSell15,000$111.22$1,668,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015David M StackCEOSell15,000$97.52$1,462,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Paul J HastingsDirectorSell2,500$94.06$235,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2014John P Phd LongeneckerDirectorSell1,000$93.32$93,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2014Dennis L WingerDirectorBuy2,645$94.54$250,058.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2014James S ScibettaCFOSell15,000$87.18$1,307,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2014Taunia MarkvickaSVPBuy230$86.62$19,922.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Paul J HastingsDirectorSell2,500$94.87$237,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014John P Phd LongeneckerDirectorSell1,000$96.40$96,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2014Andreas WickiDirectorSell21,494$108.11$2,323,716.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Andreas WickiDirectorSell55,813$108.08$6,032,269.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Andreas WickiDirectorSell24,207$108.11$2,617,018.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Andreas WickiDirectorSell30,000$108.07$3,242,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Andreas WickiDirectorSell150,000$101.25$15,187,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/8/2014James S ScibettaCFOSell15,000$99.63$1,494,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Gary PatouInsiderSell20,000$100.26$2,005,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2014David M StackCEOSell15,000$86.75$1,301,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2014Gary PatouInsiderSell29,700$86.96$2,582,712.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Paul J HastingsDirectorSell2,500$84.41$211,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2014Andreas WickiDirectorSell67,900$82.62$5,609,898.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014Andreas WickiDirectorSell68,000$80.69$5,486,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014Andreas WickiDirectorSell64,400$77.93$5,018,692.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014Andreas WickiDirectorSell3,600$77.80$280,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014Gary PatouInsiderSell30,000$74.39$2,231,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014David StackCEOSell25,000$73.94$1,848,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014Laura BregeDirectorSell10,000$73.85$738,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Andreas WickiDirectorSell23,220$75.76$1,759,147.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014James ScibettaCFOSell15,000$75.05$1,125,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2014Andreas WickiDirectorSell44,780$75.78$3,393,428.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/28/2014John Phd LongeneckerDirectorSell1,000$64.63$64,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014Andreas WickiDirectorSell24,887$80.16$1,994,941.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2013David StackCEOSell15,000$55.84$837,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2013James ScibettaCFOSell10,000$55.55$555,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2013John Phd LongeneckerDirectorSell2,500$55.55$138,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2013Gary PatouInsiderSell20,000$48.92$978,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2013Andreas WickiDirectorSell17,783$37.25$662,416.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Taunia MarkvickaVPSell14,700$37.00$543,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2013Andreas WickiDirectorSell75,958$35.06$2,663,087.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2013Andreas WickiDirectorSell25,560$33.45$854,982.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2013Andreas WickiDirectorSell48,482$33.28$1,613,480.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2013Taunia MarkvickaVPSell29,754$32.00$952,128.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/11/2013Andreas WickiDirectorSell80,000$31.48$2,518,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2013Andreas WickiDirectorSell44,021$30.80$1,355,846.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2013Andreas WickiDirectorSell114,448$30.21$3,457,474.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2013Gary PatouInsiderSell40,000$29.44$1,177,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2013David M StackCEOSell15,000$28.73$430,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2013James S ScibettaCFOSell10,000$28.05$280,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2013John P Phd LongeneckerDirectorSell2,000$28.09$56,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2013Fred A MiddletonDirectorSell75,900$29.13$2,210,967.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2013Fred A MiddletonDirectorSell144,100$29.32$4,225,012.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013Andreas WickiDirectorSell35,407$29.90$1,058,669.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2013Andreas WickiDirectorSell50,145$29.86$1,497,329.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2013John PrattInsiderSell21,032$30.00$630,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2013Luke EvninDirectorSell22,746$30.07$683,972.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Andreas WickiDirectorSell4,409$30.00$132,270.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013Andreas WickiDirectorSell11,500$30.00$345,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2013John PrattInsiderSell18,343$30.00$550,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013Andreas WickiDirectorSell15,500$30.26$469,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Andreas WickiDirectorSell1,900$30.00$57,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2013Luke EvninDirectorSell54,517$30.00$1,635,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2013Luke EvninDirectorSell215,528$30.86$6,651,194.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2013Andreas WickiDirectorSell18,471$30.00$554,130.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2013Andreas WickiDirectorSell14,374$30.00$431,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2013Andreas WickiDirectorSell290,900$27.95$8,130,655.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateHeadline
07/28/16 06:01 PMCan Shares Of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Hit $105? - Investor Newswire
07/22/16 05:36 PMThe Statistics Don't Lie: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Earnings Preview - The Voice Registrar
07/21/16 06:05 PMIs $105 Price Target Attainable For Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)? - Investor Newswire
07/21/16 06:05 PMAnalysts Reviewing Stocks: CVS Health Corporation (NYSE:CVS) , Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Street Updates
07/21/16 06:05 PMPacira Pharmaceuticals Inc. (PCRX) Jumps 7.96% on July 20 - Equities.com
07/21/16 06:05 PMPacira Pharmaceuticals Inc (NASDAQ:PCRX) Realized Volatility Hits A Notable High - CML News
07/19/16 06:09 AMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Expected To Post Sales Of $1127.9 - Investor Newswire
07/17/16 09:57 AMShares Experiencing a Downtrend: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - TGP
07/15/16 10:49 AMPacira Pharmaceuticals Inc. (PCRX) Drops 5.87% on July 13 - Equities.com
07/15/16 06:58 AMPacira Pharmaceuticals Announces Timing for Second Quarter 2016 Financial Results Webcast and Conference Call - [at noodls] - PARSIPPANY, N.J., July 15, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company's second quarter ended June 30, 2016 will be released ...
07/14/16 09:22 AMStrong Sell Calls For Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) At 0 - Investor Newswire
07/13/16 06:07 PMIs Pacira Pharmaceuticals Inc a Sell? The Stock Declines Again - Press Telegraph
07/12/16 10:06 AMTrading Performance and Target Watch for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Press Telegraph
07/11/16 05:44 PMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/11/16 05:44 PMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Yearly Sales Target At $1127.9 - Investor Newswire
07/11/16 05:44 PMStock Performance Rundown on: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Press Telegraph
07/11/16 05:44 PMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Broker Price Targets For The Coming Week - Fiscal Standard
07/08/16 05:46 PMNext Century Growth Investors LLC Increased Pacira Pharmaceuticals (NASDAQ:PCRX) by $14.12 Million as Shares ... - Press Telegraph
07/08/16 05:46 PMPacira Pharmaceuticals Inc. (PCRX) Jumps 5.14% on July 06 - Equities.com
07/06/16 05:56 PMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Expected to Reach Highs Of $105 - Investor Newswire
07/06/16 10:22 AMStock Rating Watch and Earnings Insight for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Press Telegraph
07/05/16 05:30 PMShare Volatility in Focus: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Engelwood Daily
07/05/16 10:14 AMHC Stocks to watch for: Pacira Pharmaceuticals Inc (NASDAQ:PCRX), Sarepta Therapeutics Inc (NASDAQ:SRPT) - share market updates (press release)
07/03/16 05:07 PMShare Performance Recap for: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Press Telegraph
07/02/16 05:24 PMPacira Pharmaceuticals Inc. (PCRX) Drops 11.26% on June 30 - Equities.com
07/02/16 08:30 AMExparel Concerns Weigh On Pacira Pharma, Brean Moves To Sidelines
07/01/16 05:45 PMTracking Stock Volatility for: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Engelwood Daily
07/01/16 06:37 AMPACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclo -
06/29/16 05:39 PMAnalyst Update: Pacira Pharmaceuticals Inc, McKesson Corporation, and Newfield Exploration Co.
06/29/16 04:11 PMPacira Shares Tumble Following BMO's New Underperform Rating - BMO analyst Gary Nachman initiated coverage on shares of Pacira Pharmaceuticals Inc (NASDAQ: PCRX) with an Underperform rating and $36 price target Wednesday. Nachman showed concern the Street's current consensus estimate for Exparel sits "too high." Although he called Exparel "a very solid product for post-surgical pain," he warned "further penetration at the hospitals has become more ...Full story available on Benzinga.com
06/27/16 05:45 PMNew Market Report: Pacira Pharmaceuticals, Inc. (PCRX) - Financial and Strategic SWOT Analysis Review
06/26/16 04:53 PMMany Growth Catalysts For Pacira - Seeking Alpha
06/26/16 04:53 PMStock Performance Focus on: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Press Telegraph
06/23/16 09:55 AMA Biotech and a Medical Device Stock, Each With Massive Upside Potential -
06/20/16 07:21 AMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 03:13 PMPACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to -
06/16/16 05:59 PMPerformance watch list: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - News Oracle
06/16/16 05:59 PMEarnings Review: Ceres, Inc. (NASDAQ:CERE), Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Beacon Chronicle
06/15/16 05:42 PMRelative Strength Alert For Pacira Pharmaceuticals
06/09/16 06:06 PMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Fundamental Star Rating Report - CML News
06/05/16 05:45 PMPerformance Review for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - HNN
06/04/16 05:49 PMWill Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Surprise Analysts? - Investor Newswire
06/04/16 08:38 AMTwo Healthcare stocks to Focus: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) , Impax Laboratories, Inc. (NASDAQ ... - Is stories
06/02/16 06:09 PMBroker Watchlist: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Share Trading News - Broker Watchlist: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)Share Trading News01/29/2015 – Pacira Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Goldman Sachs. They now have a USD 126 price target on the stock. The share price of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was up +1.78% during the last ...Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Quarterly EBIT At $-2.254 MillionsVanguard TribuneMichael Kors Holdings Limited (NYSE:KORS) surged 6.60%: ConocoPhillips (NYSE:COP), Pacira Pharmaceuticals, Inc ...KC Registerall 3 news articles »
06/01/16 06:16 PMPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Quarterly EPS Estimate At $0.04 - Investor Newswire - Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Quarterly EPS Estimate At $0.04Investor NewswireFirst Call stated that Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) can touch $79.67 in coming one year. For the next quarter, the per-share earnings target is $0.04 and for ongoing fiscal at $0.33. EPS target for next year is $1.82 versus the mean EPS ...and more »
06/01/16 08:41 AMStock Review and Earnings Check on Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - HNN - Stock Review and Earnings Check on Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Pacira Pharmaceuticals, Inc.and more »
05/31/16 06:02 PMStocks Recent Trading Summary: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) , Regeneron Pharmaceuticals, Inc ... - Street Updates - Stocks Recent Trading Summary: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) , Regeneron Pharmaceuticals, Inc ...Street UpdatesPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) accumulated +4.26%, closing at $45.56 after floating between $43.85 and $45.70. The company has market capitalization of $1.69B. It has twelve month low of $35.78 and twelve month high of $81.28.and more »
05/31/16 01:32 PMHedge Funds Hated These Healthcare Stocks in Q1 -
05/31/16 06:42 AMPacira Pharmaceuticals, Inc. to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - PARSIPPANY, N.J., May 31, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled ...
05/30/16 10:08 PMStock Rating Review for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - HNN - Stock Rating Review for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)HNNInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1.25 on shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Covering ...and more »

Social

About Pacira Pharmaceuticals

Pacira Pharmaceuticals logoPacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company's lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: PCRX
  • CUSIP: 69512710
Key Metrics:
  • Previous Close: $36.25
  • 50 Day Moving Average: $37.62
  • 200 Day Moving Average: $50.48
  • P/E Ratio: N/A
  • P/E Growth: 1.69
  • Market Cap: $1.35B
  • Beta: 1.65
  • Current Year EPS Consensus Estimate: $-0.55 EPS
  • Next Year EPS Consensus Estimate: $0.62 EPS
Additional Links:
Pacira Pharmaceuticals (NASDAQ:PCRX) Chart for Saturday, July, 30, 2016